Persistent Fetal SVT in a COVID-19 Positive Pregnancy
Author(s) -
Gloria Wang,
Eric Stapley,
Sara Peterson,
Jessica Parrott,
Cecily A. Clark-Ganheart
Publication year - 2022
Publication title -
case reports in obstetrics and gynecology
Language(s) - English
Resource type - Journals
eISSN - 2090-6692
pISSN - 2090-6684
DOI - 10.1155/2022/9933520
Subject(s) - medicine , covid-19 , pregnancy , fetus , obstetrics , virology , genetics , biology , infectious disease (medical specialty) , disease , outbreak
Background. Rapid introduction and spread of SARS-CoV-2 have posed unique challenges in understanding the disease, role in vertical transmission, and in developing management. We present a case of a patient with COVID-19 infection and fetus with new-onset fetal SVT. Case. A 26-year-old gravida 4 para 2012 with third trimester COVID-19 infection was diagnosed with new onset fetal SVT. Successful cardioversion was achieved with flecainide. The patient was followed outpatient until induction of labor at 39 and 3/7 weeks of gestational age resulting in an uncomplicated vaginal delivery. Postpartum course was uncomplicated. Conclusion. Fetal SVT is a potential complication of maternal COVID-19 infection. The use of transplacental therapy with flecainide is an appropriate alternative to digoxin in these cases.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom